These cancer-specific polarization patterns, along with CD68’s strong immune correlations, suggest tailored immunotherapy approaches - particularly combining polarization modulators (e.g., CSF-1R inhibitors) with PD-1 blockade - should be developed based on tumor-type macrophage profiles. The gene discussed is CD68; the disease is neoplasm.